1. Navigate to /generics-bulletin
  2. Navigate to /generics-bulletin/archive

AMR report depicts industry commitment

  
Generate a summary of this article
Listen to this article
Beta

Medicines for Europe is among the healthcare industry stakeholders who have welcomed the first report on antimicrobial resistance (AMR) by the AMR Industry Alliance, which “brings together over 100 biotech, diagnostics, generics and research-based biopharmaceutical companies and trade associations from 20 countries” and shows that “broadly the Alliance membership is already active and making positive contributions to the challenge of AMR”.

Medicines for Europe is among the healthcare industry stakeholders who have welcomed the first report on antimicrobial resistance (AMR) by the AMR Industry Alliance, which “brings together over 100 biotech, diagnostics, generics and research-based biopharmaceutical companies and trade associations from 20 countries” and shows that “broadly the Alliance membership is already active and making positive contributions to the challenge of AMR”.

Adrian van den Hoven, director general of Medicines for Europe, said the report was a “key milestone in cementing industry...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Archive

ADHD Medications and Cardiovascular Effects: New Data Revealed. (A Comprehensive Evaluation of Emerging Clinical and Epidemiological Evidence on the Cardiovascular Effects Associated with Prescribed Medications for Attention Deficit Hyperactivity Disorder) - Clone - Clone

 
• By Nabil

A look at new research on the cardiovascular effects of ADHD medications and what it means for clinical care. This article explores the latest clinical and epidemiological research on the cardiovascular effects of medications commonly prescribed for ADHD, examining potential heart-related risks, underlying mechanisms, and their implications for patient safety, clinical decision-making, and long-term treatment strategies across diverse age groups and risk profiles.

Testing-Rising

 
• By Saba Afreen

Testing-Rising xxxx

bhvyuguig

lnkbkb

test 1

test 1

More from Generics Bulletin

UK Invests £28m In NHS AI, But Industry Says Procurement And Training Will Determine Success - C9

 
• By Reed Miller

The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.

UK Invests £28m In NHS AI, But Industry Says Procurement And Training Will Determine Success - C8

 
• By Reed Miller

The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.

UK Invests £28m In NHS AI, But Industry Says Procurement And Training Will Determine Success - C7

 
• By Reed Miller

The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.